JHP Pharmaceuticals and SpePharm complete purchase of
Dantrium®
Parsippany, NJ and Amsterdam, The Netherlands,
August 20, 2008 – JHP Pharmaceuticals, LLC
and SpePharm Holding, BV announced today the
successful closing of an asset purchase
agreement, pursuant to which JHP and SpePharm
acquired global rights to Procter and Gamble’s
Dantrium® product (dantrolene sodium). In its
intravenous form, Dantrium is used to treat
malignant hyperthermia (a life-threatening
reaction to certain gaseous anesthetics) and in
its oral form, the control of clinical
spasticity resulting from upper motor neuron
disorders (e.g., spinal cord injury, stroke,
cerebral palsy, or multiple sclerosis).
JHP Pharmaceuticals LLC acquired the rights to
Dantrium for the US and Canada, including supply
rights in Australia, New Zealand, Israel and
Chile while SpePharm Holding, BV acquired the
rights in the rest of the world.
Stuart Hinchen, President of JHP commented:
“We are delighted to acquire the rights to
Dantrium. This product will fit well into our
current portfolio of marketed products which
already includes exports to Canada and
Australia.”
Jean-Francois Labbé, Chief Executive Officer of
SpePharm, said:
“We have been pleased to partner with JHP in
this acquisition and secure Procter & Gamble’s
rights to Dantrium in the rest of the world
(excluding the JHP territories). In Europe
Dantrium will receive support from SpePharm’s
growing hospital sales and marketing
infrastructure.”
About JHP Pharmaceuticals, LLC
JHP, headquartered in New Jersey, is a
specialty pharmaceutical company which
manufactures and sells pharmaceutical products,
primarily aseptic injectable products into the
hospital segment, and provides contract
manufacturing of sterile products for innovator
pharmaceutical companies. JHP is a private
company wholly owned by JHP Holdings, LLC whose
equity owners are Morgan Stanley Principal
Investments, Peter Jenkins and Stuart Hinchen.
About SpePharm Holding, BV
SpePharm Holding, B.V. is a Dutch company with
its registered office in Amsterdam, and its
European operations based in Paris, France.
SpePharm is an emerging pan-European specialty
pharmaceutical company focused on acquiring,
registering and marketing high medical value
specialty medicines essentially for the hospital
market. Particular areas of therapeutic interest
are oncology, critical and supportive care.
SpePharm was founded in September 2006 by
Jean-François Labbé together with leading life
science investment firms TVM Capital and Signet
Healthcare Partners (part of the Sanders Morris
Harris Group). Paul Capital Healthcare, one of
the largest dedicated healthcare investors
globally, made an equity investment in SpePharm
in August 2008, and provided additional
non-dilutive financing for SpePharm to acquire
the rights to Dantrium. Jean-François Labbé is a
former top executive of Hoechst Marion Roussel
and Parke Davis with over 30 years of experience
in international pharmaceutical management. To
date SpePharm has an established commercial
presence in the UK, Germany, Italy, Benelux and
the Nordic area where it currently launches its
first product, Loramyc, for the treatment of
oropharyngeal candidiasis in immune-compromised
patients.
For more
information about SpePharm, please visit the web
site at
www.spepharm.com
Additional Press Releases
 |
JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage
|
PDF Format |
|
|
JHP Pharmaceuticals Announces Successful
Completion of FDA and EMEA GMP Audits
Webpage
|
PDF Format |
|
|
JHP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
Webpage
|
PDF Format |
|
|
JHP Pharmaceuticals & SpePharm complete
purchase
of Dantrium® (dantrolene sodium)
Webpage
|
PDF Format |
|
|
King Pharmaceuticals To Sell Rochester,
Michigan Manufacturing Facility To JHP
Pharmaceuticals
Webpage
|
PDF Format |
Return To Press & News
»
